AID downregulation is a novel function of the DNMT inhibitor 5-aza-deoxycytidine

Oncotarget

Volumn 5, Issue 1, 2014, Pages 211-223

  Tsai, Chiou Tsun ^a   Yang, Pei Ming ^a   Chern, Ting Rong ^b   Chuang, Shu Hui ^a   Lin, Jung Hsin ^a,b,c   Klemm, Lars ^d   Müschen, Markus ^d   Chen, Ching Chow ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b RESEARCH CENTER FOR APPLIED SCIENCES   (Taiwan)

^c INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

5 aza CdR; AID; DNMT1; Zebularine

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ACTIVATION INDUCED CYTIDINE DEAMINASE; PROTEIN P21; SINGLE STRANDED DNA; ZEBULARINE; AICDA (ACTIVATION-INDUCED CYTIDINE DEAMINASE); AZACITIDINE; CYTIDINE DEAMINASE; DNA (CYTOSINE 5) METHYLTRANSFERASE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE 1; ENZYME INHIBITOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL VIABILITY ASSAY; DOWN REGULATION; DRUG CYTOTOXICITY; ENZYME ACTIVE SITE; HEMATOPOIETIC CELL; HUMAN; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; IN VIVO STUDY; MOLECULAR DOCKING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; METABOLISM; MOUSE; NONOBESE DIABETIC MOUSE; SCID MOUSE; XENOGRAFT;

ANIMALS; AZACITIDINE; CYTIDINE DEAMINASE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DOWN-REGULATION; ENZYME INHIBITORS; HETEROGRAFTS; HUMANS; MICE; MICE, INBRED NOD; MICE, SCID; MOLECULAR DOCKING SIMULATION;

EID: 84893874694     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1319     Document Type: Article

References (50)

1. Perez-Duran P, de Yebenes VG and Ramiro AR. Oncogenic events triggered by AID, the adverse effect of antibody diversification. Carcinogenesis. 2007; 28(12):2427-2433.
2. Honjo T, Muramatsu M and Fagarasan S. AID: how does it aid antibody diversity? Immunity. 2004; 20(6):659-668.
3. Kinoshita K and Nonaka T. The dark side of activation-induced cytidine deaminase: relationship with leukemia and beyond. International journal of hematology. 2006; 83(3):201-207.
4. Ramiro AR, Jankovic M, Callen E, Difilippantonio S, Chen HT, McBride KM, Eisenreich TR, Chen J, Dickins RA, Lowe SW, Nussenzweig A and Nussenzweig MC. Role of genomic instability and p53 in AID-induced c-myc-Igh translocations. Nature. 2006; 440(7080):105-109.
5. Takizawa M, Tolarova H, Li Z, Dubois W, Lim S, Callen E, Franco S, Mosaico M, Feigenbaum L, Alt FW, Nussenzweig A, Potter M and Casellas R. AID expression levels determine the extent of cMyc oncogenic translocations and the incidence of B cell tumor development. The Journal of experimental medicine. 2008; 205(9):1949-1957.
6. Klemm L, Duy C, Iacobucci I, Kuchen S, von Levetzow G, Feldhahn N, Henke N, Li Z, Hoffmann TK, Kim YM, Hofmann WK, Jumaa H, Groffen J, Heisterkamp N, Martinelli G, Lieber MR, et al. The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia. Cancer Cell. 2009; 16(3):232-245.
7. Feldhahn N, Henke N, Melchior K, Duy C, Soh BN, Klein F, von Levetzow G, Giebel B, Li A, Hofmann WK, Jumaa H and Muschen M. Activation-induced cytidine deaminase acts as a mutator in BCR-ABL1-transformed acute lymphoblastic leukemia cells. The Journal of experimental medicine. 2007; 204(5):1157-1166.
8. Quintas-Cardama A and Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood. 2009; 113(8):1619-1630.
9. Garcia-Manero G, Faderl S, O'Brien S, Cortes J, Talpaz M and Kantarjian HM. Chronic myelogenous leukemia: a review and update of therapeutic strategies. Cancer. 2003; 98(3):437-457.
10. Gruber TA, Chang MS, Sposto R and Muschen M. Activation-induced cytidine deaminase accelerates clonal evolution in BCR-ABL1-driven B-cell lineage acute lymphoblastic leukemia. Cancer Res. 2010; 70(19):7411-7420.
11. Komeno Y, Kitaura J, Watanabe-Okochi N, Kato N, Oki T, Nakahara F, Harada Y, Harada H, Shinkura R, Nagaoka H, Hayashi Y, Honjo T and Kitamura T. AID-induced T-lymphoma or B-leukemia/lymphoma in a mouse BMT model. Leukemia. 2010; 24(5):1018-1024.
12. Sorm F, Piskala A, Cihak A and Vesely J. 5-Azacytidine, a new, highly effective cancerostatic. Experientia. 1964; 20(4):202-203.
13. Santi DV, Norment A and Garrett CE. Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine. Proc Natl Acad Sci U S A. 1984; 81(22):6993-6997.
14. Ghoshal K, Datta J, Majumder S, Bai S, Kutay H, Motiwala T and Jacob ST. 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal. Mol Cell Biol. 2005; 25(11):4727-4741.
15. Claus R and Lubbert M. Epigenetic targets in hematopoietic malignancies. Oncogene. 2003; 22(42):6489-6496.
16. Momparler RL, Momparler LF and Samson J. Comparison of the antileukemic activity of 5-AZA-2'-deoxycytidine, 1-beta-D-arabinofuranosylcytosine and 5-azacytidine against L1210 leukemia. Leukemia research. 1984; 8(6):1043-1049.
17. Laliberte J, Marquez VE and Momparler RL. Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-2'-deoxycytidine by human cytidine deaminase. Cancer Chemother Pharmacol. 1992; 30(1):7-11.
18. Chabner BA, Drake JC and Johns DG. Deamination of 5-azacytidine by a human leukemia cell cytidine deaminase. Biochem Pharmacol. 1973; 22(21):2763-2765.
19. Kim CH, Marquez VE, Mao DT, Haines DR and McCormack JJ. Synthesis of pyrimidin-2-one nucleosides as acid-stable inhibitors of cytidine deaminase. J Med Chem. 1986; 29(8):1374-1380.
20. Carlow D and Wolfenden R. Substrate connectivity effects in the transition state for cytidine deaminase. Biochemistry (Mosc). 1998; 37(34):11873-11878.
21. Prochnow C, Bransteitter R, Klein MG, Goodman MF and Chen XS. The APOBEC-2 crystal structure and functional implications for the deaminase AID. Nature. 2007; 445(7126):447-451.
22. Xu Z, Fulop Z, Wu G, Pone EJ, Zhang J, Mai T, Thomas LM, Al-Qahtani A, White CA, Park SR, Steinacker P, Li Z, Yates J, 3rd, Herron B, Otto M, Zan H, et al. 14-3-3 adaptor proteins recruit AID to 5'-AGCT-3'-rich switch regions for class switch recombination. Nat Struct Mol Biol. 2010; 17(9):1124-1135.
23. Aoufouchi S, Faili A, Zober C, D'Orlando O, Weller S, Weill JC and Reynaud CA. Proteasomal degradation restricts the nuclear lifespan of AID. J Exp Med. 2008; 205(6):1357-1368.
24. Patenaude AM, Orthwein A, Hu Y, Campo VA, Kavli B, Buschiazzo A and Di Noia JM. Active nuclear import and cytoplasmic retention of activation-induced deaminase. Nature structural&molecular biology. 2009; 16(5):517-527.
25. Ito S, Nagaoka H, Shinkura R, Begum N, Muramatsu M, Nakata M and Honjo T. Activation-induced cytidine deaminase shuttles between nucleus and cytoplasm like apolipoprotein B mRNA editing catalytic polypeptide 1. Proceedings of the National Academy of Sciences of the United States of America. 2004; 101(7):1975-1980.
26. Leuenberger M, Frigerio S, Wild PJ, Noetzli F, Korol D, Zimmermann DR, Gengler C, Probst-Hensch NM, Moch H and Tinguely M. AID protein expression in chronic lymphocytic leukemia/small lymphocytic lymphoma is associated with poor prognosis and complex genetic alterations. Mod Pathol. 2010; 23(2):177-186.
27. McCarthy H, Wierda WG, Barron LL, Cromwell CC, Wang J, Coombes KR, Rangel R, Elenitoba-Johnson KS, Keating MJ and Abruzzo LV. High expression of activation-induced cytidine deaminase (AID) and splice variants is a distinctive feature of poor-prognosis chronic lymphocytic leukemia. Blood. 2003; 101(12):4903-4908.
28. Chuang LS, Ian HI, Koh TW, Ng HH, Xu G and Li BF. Human DNA-(cytosine-5) methyltransferase-PCNA complex as a target for p21WAF1. Science. 1997; 277(5334):1996-2000.
29. Leonhardt H, Page AW, Weier HU and Bestor TH. A targeting sequence directs DNA methyltransferase to sites of DNA replication in mammalian nuclei. Cell. 1992; 71(5):865-873.
30. Smallwood A, Esteve PO, Pradhan S and Carey M. Functional cooperation between HP1 and DNMT1 mediates gene silencing. Genes Dev. 2007; 21(10):1169-1178.
31. Jeevan-Raj BP, Robert I, Heyer V, Page A, Wang JH, Cammas F, Alt FW, Losson R and Reina-San-Martin B. Epigenetic tethering of AID to the donor switch region during immunoglobulin class switch recombination. J Exp Med. 2011; 208(8):1649-1660.
32. Esteve PO, Chin HG, Benner J, Feehery GR, Samaranayake M, Horwitz GA, Jacobsen SE and Pradhan S. Regulation of DNMT1 stability through SET7-mediated lysine methylation in mammalian cells. Proceedings of the National Academy of Sciences of the United States of America. 2009; 106(13):5076-5081.
33. Kar S, Deb M, Sengupta D, Shilpi A, Parbin S, Torrisani J, Pradhan S and Patra S. An insight into the various regulatory mechanisms modulating human DNA methyltransferase 1 stability and function. Epigenetics. 2012; 7(9):994-1007.
34. Esteve PO, Chang Y, Samaranayake M, Upadhyay AK, Horton JR, Feehery GR, Cheng X and Pradhan S. A methylation and phosphorylation switch between an adjacent lysine and serine determines human DNMT1 stability. Nature structural&molecular biology. 2011; 18(1):42-48.
35. Basu U, Franklin A and Alt FW. Post-translational regulation of activation-induced cytidine deaminase. Philos Trans R Soc Lond B Biol Sci. 2009; 364(1517):667-673.
36. Cui X, Lu Z, Kurosawa A, Klemm L, Bagshaw AT, Tsai AG, Gemmell N, Muschen M, Adachi N, Hsieh CL and Lieber MR. Both CpG methylation and activation-induced deaminase are required for the fragility of the human bcl-2 major breakpoint region: implications for the timing of the breaks in the t(14;18) translocation. Molecular and cellular biology. 2013; 33(5):947-957.
37. Nagaoka H, Tran TH, Kobayashi M, Aida M and Honjo T. Preventing AID, a physiological mutator, from deleterious activation: regulation of the genomic instability that is associated with antibody diversity. Int Immunol. 2010; 22(4):227-235.
38. Delker RK, Zhou Y, Strikoudis A, Stebbins CE and Papavasiliou FN. Solubility-based genetic screen identifies RING finger protein 126 as an E3 ligase for activation-induced cytidine deaminase. Proceedings of the National Academy of Sciences of the United States of America. 2013; 110(3):1029-1034.
39. Uchimura Y, Barton LF, Rada C and Neuberger MS. REG-gamma associates with and modulates the abundance of nuclear activation-induced deaminase. J Exp Med. 2011; 208(12):2385-2391.
40. Momparler RL and Derse D. Kinetics of phosphorylation of 5-aza-2'-deoxyycytidine by deoxycytidine kinase. Biochemical pharmacology. 1979; 28(8):1443-1444.
41. Van Rompay AR, Norda A, Linden K, Johansson M and Karlsson A. Phosphorylation of uridine and cytidine nucleoside analogs by two human uridine-cytidine kinases. Molecular pharmacology. 2001; 59(5):1181-1186.
42. Ben-Kasus T, Ben-Zvi Z, Marquez VE, Kelley JA and Agbaria R. Metabolic activation of zebularine, a novel DNA methylation inhibitor, in human bladder carcinoma cells. Biochem Pharmacol. 2005; 70(1):121-133.
43. Lee T, Karon M and Momparler RL. Kinetic studies on phosphorylation of 5-azacytidine with the purified uridine-cytidine kinase from calf thymus. Cancer Res. 1974; 34(10):2482-2488.
44. Schermelleh L, Spada F, Easwaran HP, Zolghadr K, Margot JB, Cardoso MC and Leonhardt H. Trapped in action: direct visualization of DNA methyltransferase activity in living cells. Nat Methods. 2005; 2(10):751-756.
45. Lubbert M. DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action. Curr Top Microbiol Immunol. 2000; 249:135-164.
46. Saba HI. Decitabine in myeloid malignancies. Hematology Meeting Reports. 2008; 2(5):1-8.
47. Issa JP, Gharibyan V, Cortes J, Jelinek J, Morris G, Verstovsek S, Talpaz M, Garcia-Manero G and Kantarjian HM. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol. 2005; 23(17):3948-3956.
48. Kantarjian HM, O'Brien S, Cortes J, Giles FJ, Faderl S, Issa JP, Garcia-Manero G, Rios MB, Shan J, Andreeff M, Keating M and Talpaz M. Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer. 2003; 98(3):522-528.
49. Oki Y, Kantarjian HM, Gharibyan V, Jones D, O'Brien S, Verstovsek S, Cortes J, Morris GM, Garcia-Manero G and Issa JP. Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. Cancer. 2007; 109(5):899-906.
50. Revy P, Muto T, Levy Y, Geissmann F, Plebani A, Sanal O, Catalan N, Forveille M, Dufourcq-Labelouse R, Gennery A, Tezcan I, Ersoy F, Kayserili H, Ugazio AG, Brousse N, Muramatsu M, et al. Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2). Cell. 2000; 102(5):565-575.